Maine drug disposal bill dies
This article was originally published in The Tan Sheet
Executive SummaryThe Maine Senate indefinitely postpones legislation passed by the House that would have impelled manufacturers to contribute to an "Unused Pharmaceutical Disposal Program Fund." The Senate placed LD 821 in legislative files March 26, effectively killing it. The Consumer Healthcare Products Association opposed the bill and favors consumer education on safe drug disposal (1"The Tan Sheet" March 22, 2010, In Brief)
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.